secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2022-11-16T23:59:59+00:00
Accession:  0001628280-22-030171
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus warns of $185M-$205M impairment, rebate dispute; evaluating going concern
--------------------------------------------------------------------------------

- Preliminary review indicates a non-cash impairment charge of $185M to $205M for Q3 2022.
- Disputed rebate invoice from a large private payer in Pain Treatments likely to reduce Q3 revenue and may affect revenue guidance.
- Management concludes internal controls for quarterly rebate recognition were inadequate for period ended Oct 1, 2022.
- Evaluating ability to meet financial obligations within one year; considering mitigation steps.
- Expects to file Form 10-Q by Nov 21, 2022, using 12b-25 extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022030171/0001628280-22-030171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828022030171/bvs-20221116.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-030171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer